A detailed history of American Century Companies Inc transactions in Uni Qure N.V. stock. As of the latest transaction made, American Century Companies Inc holds 67,699 shares of QURE stock, worth $434,627. This represents 0.0% of its overall portfolio holdings.

Number of Shares
67,699
Previous 59,057 14.63%
Holding current value
$434,627
Previous $307,000 1.3%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

BUY
$4.39 - $5.43 $37,938 - $46,926
8,642 Added 14.63%
67,699 $303,000
Q1 2024

May 14, 2024

BUY
$4.82 - $6.93 $70,184 - $100,907
14,561 Added 32.72%
59,057 $307,000
Q4 2023

Feb 13, 2024

BUY
$5.63 - $8.27 $250,512 - $367,981
44,496 New
44,496 $301,000
Q3 2023

Nov 13, 2023

BUY
$6.71 - $11.83 $39,575 - $69,773
5,898 Added 21.63%
33,164 $222,000
Q2 2023

Aug 14, 2023

BUY
$11.12 - $22.2 $103,582 - $206,793
9,315 Added 51.89%
27,266 $312,000
Q1 2023

May 11, 2023

BUY
$18.7 - $23.07 $7,274 - $8,974
389 Added 2.22%
17,951 $361,000
Q4 2022

Feb 13, 2023

SELL
$18.12 - $27.32 $2.88 Million - $4.35 Million
-159,126 Reduced 90.06%
17,562 $398,000
Q3 2022

Nov 14, 2022

SELL
$16.98 - $25.54 $1.76 Million - $2.65 Million
-103,920 Reduced 37.03%
176,688 $3.32 Million
Q2 2022

Aug 12, 2022

BUY
$13.15 - $20.45 $826,648 - $1.29 Million
62,863 Added 28.87%
280,608 $5.23 Million
Q1 2022

May 11, 2022

BUY
$14.54 - $21.5 $676,517 - $1 Million
46,528 Added 27.17%
217,745 $3.94 Million
Q4 2021

Feb 07, 2022

BUY
$20.24 - $36.01 $2.79 Million - $4.97 Million
138,040 Added 416.07%
171,217 $3.55 Million
Q3 2021

Nov 10, 2021

BUY
$26.01 - $38.22 $862,933 - $1.27 Million
33,177 New
33,177 $1.06 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track American Century Companies Inc Portfolio

Follow American Century Companies Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

News

Stay updated on American Century Companies Inc with notifications on news.